# US 2006/0068457 A1 · Substrates for tafi (a)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0068457 A1
- Document ID: US20060068457A1
- Status: Published application
- Kind: A1
- Application number: 10/530,165
- Filed: 2002-12-06
- Published: 2006-03-30
- Earliest claimed: 2002-12-06
- Assignees: Dsm IP Assets B.V.
- Inventors: Hugo Ziegler; Dagmar Prasa; Jorg Sturzebecher; Peter Wilkstroem
- Web page: https://patentgrep.com/patent/US20060068457A1

## CPC

- C07K 5/06095: {Arg-amino acid}
- C07K 5/06086: {with the first amino acid being basic}
- C07K 5/06147: {and His-amino acid; Derivatives thereof}
- C07K 5/08: Tripeptides
- C07K 5/0802: {with the first amino acid being neutral}
- C12Q 1/56: involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention relates to compounds of general formula (I) and acid addition salts thereof, where the various symbols have the meanings given in the description and claims, the production and use thereof as substrate for the detection of TAFIa, a fibrinolysis inhibiting enzyme. The detection occurs by using the absorption between 400 and 412 nm, arising as a result of the formation of 3-carboxy-4-nitrothiophenol from Ellman's reagent as a function of time.

## Claims

### Claim 1

Compounds of general formula I
wherein
R1 means a CH2NH2 or NHC(NH)NH2 group,
AA2 means non-substituted or substituted lysine, ornithine, arginine or histidine, wherein the substituents are common protective groups,
AA3 means a natural amino acid in which a present, protectable group may be substituted with a usual protective group in the side chain,
n represents 0 or 1, and
R2 means a Bz, Bzl, Ac, Boc, Z, Suc, MeoSuc or Tos group,
provided that the following cases do not occur simultaneously: n=0, R1=NHC(NH)NH2, R2=Z and (AA2)=non-substituted or Boc-substituted lysine, as racemated or as enantiomeric pure isomers, and the salts thereof with mineral or organic acids.

### Claim 2 (depends on 1)

Compounds according to claim 1, wherein AA2 represents Lys(ε-Z), Lys(ε-Boc), Lys(ε-Ac), Lys(ε-Bz), Lys(ε-Bzl), Lys(ε-Tos), Orn(δ-Z), Orn(δ-Boc), Om(δ-2-chlor-Z), Orn(δ-Dnp), Orn(δ-Z), Orn(δ-Aloc), Arg(ω-Pbf), Arg(δ,ω-Boc)2, Arg(δ,ω-Z)2, Arg(ω-Tos), His(Nim-Boc), His(Nim-Ac), His(Nim-Bz),His(Nim-Bzl) or His(Nim-Tos), Lys(ε-Z) being preferred.

### Claim 3 (depends on 1, 2)

Compounds according to claim 1 or 2, wherein AA3 means Ala, Ser, Phe, Val, Ele, Leu, Thr, Pro, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys, Met, Trp, Tyr or Gly, wherein a present, protectable group may be substituted with a common protective group, such as tBu, Bzl or Ac, in the side chain.

### Claim 4 (depends on 3)

Compounds according to claim 3, wherein AA3 means Phe, Ala, Val or Ser possibly protected with tBu, Bzl or Ac.

### Claim 5 (depends on 1)

Compounds according to claim 1, wherein
R1 means NHC(NH)NH2,
AA2 means Val, Lys(s-Z) or Lys(6-Boc),
AA3 means Ala, Ser, Phe, Val, Ser(tBu), Ser(Bzl) or Ser(Ac),
n represents 0 or 1, and
R2 represents Bz, Boc or Z.

### Claim 6 (depends on 1)

Compounds according to claim 1, wherein
R1 means CH2NH2,
AA2 means Val, Lys(F-Z) or Lys(s-Boc),
AA3 means Ala, Ser, Phe, Val, Ser(tBu), Ser(Bzl) or Ser(Ac),
n represents 0 or 1, and
R2 represents Bz, Boc or Z.

### Claim 7 (depends on 1)

Compounds according to claim 1 thereby characterized that they are present as acid addition salts in the form of hydrobromides, hydrochlorides, trifluoracetates or acetates.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

Method for the determination of Thrombin-Activatable Fibrinolysis Inhibitor a (TAFIa) comprising reaction of TAFIa in the presence of 5,5′-dithiobis-(2-nitrobenzoic acid) on a compound according to claim 1 and spectrophotometric measurement of the absorption between 400 and 412 nm resulting from the formation of 3-carboxy-4-nitrothiophenol as a function of time.

### Claim 10 (depends on 9)

Method according to claim 9 thereby characterized that the reaction takes place for 5 to 15 minutes, preferably for 10 minutes at a temperature between 10° C. and 37° C., in particular at room temperature.

### Claim 11 (depends on 9)

Method according to claim 9 thereby characterized that Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) present in blood plasma is used as a source of TAFIa.

### Claim 12 (depends on 1)

Method for the preparation of formula I as defined in claim 1 comprising alkaline saponification of a corresponding alkylester.

### Claim 13 (depends on 2)

Compounds according to claim 2, wherein AA3 means Ala, Ser, Phe, Val, Ile, Leu, Thr, Pro, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys, Met, Trp, Tyr or Gly, wherein a present, protectable group may be substituted with a common protective group, such as tBu, Bzl or Ac, in the side chain.

### Claim 14 (depends on 13)

Compounds according to claim 13, wherein AA3 means Phe, Ala, Val or Ser possibly protected with tBu, Bzl or Ac.

### Claim 15 (depends on 2)

Compounds according to claim 2, wherein the compounds are present as acid addition salts in the form of hydrobromides, hydrochlorides, trifluoracetates or acetates.

### Claim 16 (depends on 3)

Compounds according to claim 3, wherein the compounds are present as acid addition salts in the form of hydrobromides, hydrochlorides, trifluoracetates or acetates.

### Claim 17 (depends on 1)

A method for the determination of Thrombin-Activatable Fibrinolysis Inhibitor a (TAFIa) comprising employing a compound according to claim 1 as a substrate for the determination of TAFIa.

### Claim 18 (depends on 1, 11)

Method according to claim 11 for the determination of TAFI in blood plasma comprising activation of this TAFI into TAFIa with thrombomodulin and thrombin bound to it, elimination of excessive thrombin activity by adding NAPAP, reaction of the resulting TAFIa in the presence of 5,5′-dithiobis-(2-nitrobenzoic acid) on a compound according to claim 1 and spectrophotometric determination of the absorption between 400 and 412 nm resulting from the formation of 3-carboxy-4-nitrothiophenol as a function of time.

### Claim 19 (depends on 1, 12)

Method according to claim 12 thereby characterized that the quantity of TAFI corresponds to 20 volume parts of a stock solution of 360 μg/ml, the quantity of thrombomodulin corresponds to 20 volume parts of a solution of 30 μg/ml, the quantity of thrombin corresponds to 20 volume parts of a solution of 2.7 U/ml, the quantity of NAPAP corresponds to 20 volume parts of a solution of 100 μM/ml, the quantity of 5,5′-dithiobis-(2-nitrobenzoic acid) corresponds to 10 volume parts of a solution of 5 mM/ml and the quantity of a compound according to claim 1 corresponds to 20 volume parts of a solution of 10 mM/ml.
